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Knowledge of the contemporary epidemiology of hepatitis C viral (HCV) infection among
military personnel can inform potential Department of Defense screening policy. HCV
infection status at the time of accession and following deployment was determined by
evaluating reposed serum from 10,000 service members recently deployed to combat operations in Iraq and Afghanistan in the period 2007-2010. A cost model was developed
from the perspective of the Department of Defense for a military applicant screening program. Return on investment was based on comparison between screening program costs
and potential treatment costs avoided. The prevalence of HCV antibody-positive and
chronic HCV infection at accession among younger recently deployed military personnel
born after 1965 was 0.98/1000 (95% confidence interval 0.45-1.85) and 0.43/1000 (95%
confidence interval 0.12-1.11), respectively. Among these, service-related incidence was
low; 64% of infections were present at the time of accession. With no screening, the cost
to the Department of Defense of treating the estimated 93 cases of chronic HCV cases
from a single year’s accession cohort was $9.3 million. Screening with the HCV antibody
test followed by the nucleic acid test for confirmation yielded a net annual savings and a
$3.1 million dollar advantage over not screening. Conclusions: Applicant screening will
reduce chronic HCV infection in the force, result in a small system costs savings, and
decrease the threat of transfusion-transmitted HCV infection in the battlefield blood supply and may lead to earlier diagnosis and linkage to care; initiation of an applicant
screening program will require ongoing evaluation that considers changes in the treatment
cost and practice landscape, screening options, and the epidemiology of HCV in the
applicant/accession and overall force populations. (HEPATOLOGY 2016;63:398-407)

E

mergent whole blood transfusion has been an
important feature of combat casualty resuscitative
care in conflicts in Iraq and Afghanistan.1 More
than 10,000 units of whole blood were used in exigent
circumstances with modified precautions not meeting

Food and Drug Administration (FDA) guidelines. The
rate of viral transmitted disease among recipients of these
non-FDA-approved blood products was assessed in a retrospective study.2 It identified a single case of transfusiontransmitted hepatitis C among 475 transfusion recipients
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tested for blood-borne viral pathogens. In a separate
study, three of 2831 donated whole blood units were hepatitis C virus (HCV)-infected.3 In a later study of transfusion recipients in this combat theater, seven individuals
had deployed while already infected with HCV.4
More broadly, prevalence of hepatitis C infection in
military service members was last determined systematically in a serologic study of specimens from the 1990s,
yielding evidence of HCV infection in approximately
five per 1000 active duty service members.5 In the intervening years, awareness of viral hepatitis and its sequelae
has increased. The Centers for Disease Control published a recent guideline expanding hepatitis C testing
to include anyone born from 1945 to 1965 regardless of
other risk status.6 Meanwhile, the US Preventive Services Task Force assessed hepatitis C screening and found
that risk factor-based screening misses patients and that
further research was needed.7
We undertook a contemporary assessment of hepatitis
C in recently deployed military forces in order to inform
potential strategies to screen military personnel with the
aims of decreasing the burden of HCV in military personnel, decreasing the threat posed by HCV-infected
personnel deployed to combat operations who may
enter the emergent non-FDA blood supply, and improving health outcomes for individuals through earlier diagnosis and linkage to care.

Materials and Methods
This was an Armed Services Blood Program Officeendorsed, Joint Staff Surgeon-tasked investigation of the
seroepidemiology of viral hepatitis (hepatitis B [HBV]
and HCV) in the deployed force. HBV and its issues are
being addressed separately. The tasking was serviceconcurred and directed at the US Army Public Center
(Provisional) (formerly US Army Public Health Command) with technical support from the Military HIV
Research Program and service counterparts, the Navy
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Bloodborne Infection Management Center, and the US
Air Force HIV Medical Evaluation Unit at San Antonio
Military Medical Center. The Walter Reed Army Institute of Research Institutional Review Board reviewed
the investigation protocol and affirmed it as a public
health activity (no. 1822).
Seroepidemiology. A random sample of 10,000
Army, Navy, Air Force, and Marine Corps service members (active and reserve components, National Guard)
who ended their most recent deployment to combat
operations in Iraq and Afghanistan in the period from
October 2007 through October 2010 was identified.
Additional inclusion criteria included (1) presence of at
least one reposed sample collected after accession in the
Department of Defense (DoD) Serum Repository,8
Armed Forces Health Surveillance Center (Silver Spring
MD). The most recently collected sample was preferentially selected and, (2) at least one “accession sample”
reposed in the DoD Serum Repository obtained prior to
entering military service from screening through a Military Entrance Processing Station or obtained within 180
days of initially entering military service of sufficient
volume.
This sample size was selected to maximize the precision
of the HCV seroprevalence estimate for the full random
sample. Assuming that the observed overall prevalence
would be equal to or less than that observed in the study
by Hyams et al., the upper limit of the 95% confidence
interval for the point estimate of the overall prevalence
would not likely exceed 1%, which was deemed to be sufficiently precise to inform DoD policy.5
For each included service member reposed serum
from the DoD Serum Repository and relevant archived
deidentified personnel, deployment, and health data
from the Defense Medical Surveillance System8 were
obtained.
Case Definitions. The following definitions of
HCV infection were employed for entry into the cost
model. (1) HCV antibody-positive: HCV antibody screen
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enzyme immunoassay (EIA)-positive and confirmed by
supplemental confirmatory antibody test. These patients
may have past or current HCV infection. (2) Chronic
HCV infection: HCV antibody screen (EIA)-positive and
confirmed by positive HCV nucleic acid testing (NAT).
Laboratory Measures. Assessment of HCV infection status was initiated with evaluation of the most
recently collected reposed serum. These samples were
tested by EIA, followed by recombinant immunoblot
assay (RIBA) confirmation. When confirmed positive,
an accession reposed sample was tested under the same
algorithm. Due to discontinuation of RIBA by the manufacturer during the course of this investigation, all
accession samples that were EIA-positive were confirmed by INNO-LIA HCV Score (Fujirebio US, Inc.).
HCV infection status was determined using the following laboratory HCV diagnostic algorithm: initial screen
was with the Ortho HCV, version 3.0, enzyme-linked
immunosorbent assay (Ortho-Clinical Diagnostics,
Inc.); reactive samples were repeated in duplicate.
Repeat reactive samples were reflexed to supplemental
confirmatory testing using the CHIRON RIBA HCV
3.0 SIA (Novartis Diagnostics) or the INNO-LIA HCV
Score. Samples that were HCV EIA repeat reactive and
RIBA-positive or INNO-LIA-positive were considered
positive for HCV infection and reflexed to HCV NAT
to distinguish chronic infection from resolved infection.
Samples that were HCV EIA repeat reactive and RIBAnegative or INNO-LIA-negative or indeterminate were
reflexed to HCV NAT to resolve indeterminate and suspected window period specimens.
Statistical Methods. Prevalence rates were assessed
for significance by constructing 95% confidence intervals. Data for service members born after 1965 were
analyzed separately from those for members born before
1966. Characteristics among service members across the
services and components were compared using the chisquared test at an alpha of 0.05. Data sets were managed
and analyzed with Statistical Analysis Software, version
9.2 (SAS Institute, Cary, NC).
Cost Modeling. We developed a decision tree
reflecting three possibilities: (1) no screening of applicants for military service, (2) screening using an EIA test
only, and (3) screening using an EIA test with an NAT
follow-up. The following assumptions impacted the
construction of the cost model.
 With no applicant screening, accessions with chronic
HCV infection will enter military service each year
and their treatment will generate health care costs to
the military health care system.
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 With either of the testing strategies, the number of
accessions with chronic HCV infection who enter
military service will be smaller than the number
with no testing.
 Some HCV-uninfected applicants will be misclassified as HCV-infected and not be allowed to enter
military service as the screening test(s) is not 100%
specific.
 Some applicants with chronic HCV infection will
be allowed to enter military service with either testing strategy because the screening test(s) is not
100% sensitive.
 In the setting of NAT following EIA, in contrast to
EIA testing alone, an increase in specificity with slight
loss in sensitivity due to testing performed in series
will result in more HCV-uninfected applicants entering military service and slightly more applicants with
chronic HCV infection entering military service.
Specific assumptions and inputs to the cost model
were derived employing the results from the seroprevalence data in this study as well as various costs and relevant statistics drawn from within the DoD and the peerreviewed scientific literature (Table 1).9 We assumed that
the test performance of both EIA and NAT is uniform
across the candidate population of potential accessions,
including in the case of NAT for the subpopulation that
already has screened positive by EIA. And we assumed
that the prevalence among all applicants, including those
who apply but do not enter military service, would be
the same as the prevalence observed among our study
population of recently deployed service members who,
by definition, were applicants who successfully entered
military service. The model addressed HCV infection as
a risk among otherwise qualified accessions, so other
exclusion criteria were not included.
We assumed that all applicants undergo screening
with HCV EIA prior to accession; all applicants with a
positive screening test receive the NAT. Based on review
of historical data and incorporating usual attrition, the
applicant pool size was assumed to be the sum of
232,000 accessions and 95,000 nonaccessions.10
We also assumed that all accessions who have chronic
HCV infection at accession would be identified during
their period of military service and treated while serving
in the armed forces. We assumed all would be genotype
1 and treated with a sofosbuvir-based regimen or equivalent according to current guidelines11 and that treatment cost would be $100,000.00.
Last, we assumed that all otherwise fully qualified
individuals who are identified with chronic HCV by an
applicant screening program and not permitted to
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Table 1. Model Inputs

Parameter

Prevalence of HCV antibodies detected by repeatedly reactive
EIA (HCV antibody repeat reactive)
Prevalence of HCV detected by HCV seropositivity confirmed by
supplemental confirmatory antibody test†
Prevalence of chronic HCV infection detected by HCV NAT
HCV screening antibody (EIA) sensitivity
HCV screening antibody (EIA) specificity
HCV NAT sensitivity
HCV NAT specificity
HCV EIA test cost/test
HCV NAT test cost/test
Annual number of applicants who apply and accession
into military service
Annual number of applicants who apply but do not accession
Cost to treat one case of chronic HCV infection
Recruitment cost per accession

Base Case Estimate
(95% Confidence Interval); A
lternate Values Considered

Source, Reference

0.16% (0.80-2.40)

Observed*

0.08% (0.02, 1.30)

Observed

0.04% (0.00-0.90);
0.06% and 0.068%
98.1% (92.6-99.7)
99.8% (99.2-99.9)
99.6% (98.9-99.9)
99.6% (n/a)
$10.84
$70.00
232,000

Observed
Derived**
Abdel-Hamid, 20029
Abdel-Hamid, 20029
APTIMA/TMA HCV kit insert
APTIMA/TMA HCV kit insert
S.A. Peel, unpublished data
S.A. Peel, unpublished data
Accession Medical Standards Analysis & Research Activity10

95,000
$100,000.00;
$83,319.00
$22,898.00

Accession Medical Standards Analysis & Research Activity10
Chhatwal et al.,19 Najafzadeh et al.,21 Rein et al.,13
J. Thomas, unpublished data

*Observed: observed among 9997 recently deployed US military personnel.
**Derived from 0.75-0.85 of observed confirmed HCV seropositivity.
†
HCV EIA repeat reactive samples confirmed with INNO-LIA.

accede would have to be replaced with another fully
qualified individual and that this would incur a burden
in rerecruitment costs of nearly $23,000 per individual
with chronic HCV infection barred from accession (J.
Thomas, unpublished data).
The net cost of screening was determined by the cost
of screening, the savings from avoiding treatment of
those who are HCV-infected who are prevented from
entering military service, and the costs of rerecruiting
applicants with positive HCV screening test results who
are not allowed to enter.
We also conducted a threshold sensitivity analysis to
calculate the minimum proportion of cases that are
prevalent at accession that must be treated while in the
armed forces for the cost of medical care averted to offset the cost of screening. This proportion was compared
to historical rates and counts of diagnoses of chronic
HCV among active-duty service members.12
Other sensitivity analyses performed included lowering the model input for cost of treatment to the lowest
published rate, $83,319.00, for current standard of care
therapeutic regimens13 and considering plausible rates
of chronic HCV infection that could be present among
future applicants that are higher than observed.

Results
Burden of HCV. Of the 10,000 randomly selected
service members, 9997 met the inclusion criteria and
had complete HCV test results generated from evalua-

tion of reposed serum; two service members had insufficient reposed sera, and one was in the Coast Guard.
Most were less than 25 years old (83%), white (74%),
and male (89%) and were in the active component
(74%) and in the Army (56%).
This sample was representative of the deployed force
and the applicant population. Age distribution reflects
that these deployed service members are slightly younger
than the overall force. After excluding those recently
deployed service members born before 1966, the demographics of the younger cohort (those born after 1965)
are similar to those of the overall population of service
members and to the applicant population.14 This sample
is also representative of the applicant population. Most
current applicants for military service are 18-25 years
old (92%), male (82%), and white (75%),10 which is
consistent with the demographics of this study sample.
Of these service members, 9224 were born after 1965
and 773 before 1966. These birth cohorts were separated in subsequent analyses regarding HCV prevalences
and their risk associations. Those results are shown in
Table 2.
There were a total of 23 chronic HCV cases present
among service members tested at the most recent time
point. Among those, 18 (78%) already were infected at
accession. All incident, service-related HCV infections
occurred among younger service members.
Among the older birth cohort, there were nine
chronic HCV cases present at the most recent sample
collection time point. Most cases were male, all were
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Table 2. Prevalence of HCV Antibody Positivity at Accession and Postdeployment Time Points
Among Recently Deployed US Military Personnel (n 5 9997*)
Birth Before 1966

Birth After 1965

Accession/Postdeployment

All
Sex
Male
Female
Race
White
Black
Other/unknown
Service
Army
Air Force
Marine Corps
Navy
Component
Active duty
National Guard
Reserve
Foreign-born
Yes
No
Unknown†
Health worker
Yes
No

No.
Tested

Accession

HCV 1

Prevalence/
1000

(95% Confidence
Interval)

No.
Tested

773

9

11.64

(5.34-21.99)

692
81

7
2

10.12
24.69

583
128
62

5
3
1

452
214
14
93

Postdeployment

HCV1

Prevalence/
1000

(95% Confidence
Interval)

HCV1

Prevalence/
1000

(95% Confidence
Interval)

9224

9

0.98

(0.45-1.85)

14

1.52

(0.83-2.55)

(4.08-20.73)
(3.00-86.36)

8196
1028

7
2

0.85
1.95

(0.34-1.76)
(0.24-7.01)

13
1

1.59
0.97

(0.84-2.71)
(0.02-5.41)

8.58
23.44
16.13

(2.79-19.90)
(4.86-66.97)
(0.41-86.62)

6782
1398
1044

8
0
1

1.18
0.00
0.96

(0.51-2.32)
(0.00-2.64)
(0.02-5.33)

12
1
1

1.77
0.72
0.96

(0.91-3.09)
(0.02-3.98)
(0.02-5.33)

9
0
0
0

19.91
0.00
0.00
0.00

(9.14-37.46)
(0.00-17.09)
(0.00-231.64)
(0.00-38.89)

5112
1636
1085
1391

6
0
1
2

1.17
0.00
0.92
1.44

(0.43-2.55)
(0.00-2.25)
(0.02-5.12)
(0.17-5.18)

10
1
1
2

1.96
0.61
0.92
1.44

(0.94-3.59)
(0.02-3.40)
(0.02-5.12)
(0.17-5.18)

337
264
172

0
5
4

0.00
18.94
23.26

(0.00-10.89)
(6.18-43.64)
(6.37-58.47)

7093
1390
741

7
1
1

0.99
0.72
1.35

(0.40-2.03)
(0.02-4.00)
(0.03-7.50)

9
3
2

1.27
2.16
2.70

(0.58-2.41)
(0.45-6.29)
(0.33-9.72)

30
222
521

1
5
3

33.33
22.52
5.76

(0.84-172.17)
(7.35-51.77)
(1.19-16.73)

737
7610
877

1
8
0

1.36
1.05
0.00

(0.03-7.54)
(0.45-2.07)
(0.00-4.20)

1
13
0

1.36
1.71
0.00

(0.03-7.54)
(0.91-2.92)
(0.00-4.20)

72
701

2
7

27.78
9.99

(3.38-96.77)
(4.02-20.47)

530
8694

1
8

1.89
0.92

(0.05-10.47)
(0.40-1.81)

1
13

1.89
1.50

(0.05-10.47)
(0.80-2.56)

*HCV antibody positive means HCV antibody repeat reactive 1 HCV antibody confirmation with supplemental confirmatory antibody test. Excluded: one Coast
Guard service member and two individuals who were not tested for HCV postdeployment.
†
Birth country unknown or missing.

present among Army soldiers in the National Guard or
Reserve component, and prevalence rates were highest
among those who were foreign-born or health workers.
However, case counts were low and the confidence intervals wide. All nine (100%) infections were present at the
time of accession.
Among the younger cohort, there were 14 chronic
HCV cases present at the most recent sample collection
time point. Prevalence rates were much lower and the
risks associated with subgroups less clear. Most cases
were male and were present among Army soldiers in the
active component. Unlike the older birth cohort, prevalence rates were higher among US-born service members
and were not significantly higher among health workers.
Nine of 14 (64%) past or current infections were present at the time of accession, and nearly one-third (5/14)
of the infections in the younger cohort were incident
infections during service (Table 3). Service members
who were HCV-infected at accession were significantly
older (n 5 9, median 29 years) than those who were not
(median 24 years) (P < 0.05).
Costs. With no screening, the cost to the armed
forces of treating the estimated 93 cases of chronic HCV

cases from a single year’s accession cohort of 232,000 was
$9.3 million. The cost of screening all 327,000 applicants, regardless of whether or not they acceded, with
HCV EIA alone is $3.5 million. Screening with HCV
EIA alone would identify 91 of the 93 cases of chronic
HCV infection among the applicant population who
acceded, which would result in a treatment cost avoided
of $9.1 million. Thus, the total cost of treatment is
reduced from $9.3 million to $0.2 million by a screening
program consisting of HCV EIA alone that costs $3.5
million. However, the additional recruiting costs required
to replace these 91 applicants who do not accede offsets
these savings by $2.1 million. Employing EIA alone,
though, has another consequence: the exclusion of 554
individuals who do not have chronic HCV infection, 89
with past or resolved HCV infection, and an additional
464 HCV-uninfected applicants with false-positive HCV
EIA screening test results. Replacement of these applicants results in an additional $12.7 million cost or a net
cost over not screening of $7.2 million.
In contrast, the combination of EIA testing followed
by NAT for EIA1 samples adds only a small incremental cost of $0.045 million because the NAT-inclusive
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Table 3. Prevalence Estimates of HCV Antibody Positivity and
Chronic HCV Infection at Accession per 1000 Personnel
Among Recently Deployed US Military Personnel
Born After 1965

HCV antibody screen-positive*
HCV antibody-positive†
Chronic HCV‡

Sample n

n

Prevalence/
1000

95% Confidence
Interval

9224
9224
9224

14
9
4

1.52
0.98
0.43

(0.86-2.49)
(0.45-1.85)
(0.12-1.11)

*HCV antibody screen-positive 5 HCV antibody repeat reactive.
HCV antibody-positive 5 HCV antibody repeat reactive 1 HCV antibody confirmation with supplemental confirmatory antibody test.
‡
Chronic HCV 5 HCV antibody repeat reactive 1 HCV nucleic acid test-positive.
†

screening strategy is only administered to the small
number of applicants with EIA1 screening test results.
With the addition of NAT, two HCV-infected applicants who would have been excluded from accessioning
under the EIA test-only scenario are allowed to enlist
and their treatment costs contribute to the total cost to
the armed forces. However, the addition of HCV NAT
permits the accessioning of 552 of the 554 applicants
who do not have chronic HCV infection and who
would not have been permitted to accede based on positive HCV EIA screening test results alone. This results
in saving most of the $12.6 million of replacement
recruitment costs. Together, the testing strategy employing an EIA test followed by NAT for positive samples
yielded a net savings and a $3.1 million advantage over
not screening. This screening strategy results in the lowest overall cost to the armed forces, a net savings over
not screening, and shifts a much higher cost associated
with treating service members with chronic HCV infection to lower costs primarily associated with screening
applicants for military service (Fig. 1).
A threshold sensitivity analysis was applied to the performance of the more cost-effective of the two screening
strategies—EIA test followed by NAT. In terms of cost
of test and treatment alone, among the 93 cases of accessions with chronic HCV infection, 42.0% (n 5 39) of
the service members who had HCV infection at the
time of accession from the no screening scenario would
have to receive care within the military health system
during their period of service in order for the screening
strategy cost to offset the treatment costs avoided. With
incorporation of rerecruitment costs this percentage
reached 57.4% (n 5 53). These numbers were less than
the average of more than 200 new cases of chronic
HCV identified each year among active duty service
members in the periods 2000-201012 and 2006- 2013
(A. Cost, personal communication).
Assuming only a lower cost of treatment ($83,319) than
the base case, screening with HCV EIA and NAT yields a
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net savings and a $1.4 million advantage over not screening. The break-even point for screening cost based upon
the number of chronic HCV-infected patients treated is
where 72.2% of the 93 HCV-infected accessions (n 5 67)
would have to receive care within the military health system during their period of service in order for the screening strategy cost to offset the treatment costs avoided.
Assuming a higher accession prevalence rate of chronic
HCV infection where 75% of the observed rate in this
study population with confirmed HCV seropositivity have
chronic HCV infection (0.75 3 0.08% 5 0.06%), screening with HCV EIA and NAT yields a net savings and a
$6.2 million advantage over not screening. The break-even
point is where 39.9% (n 5 69) of the 139 HCV-infected
accessions would have to receive care within the military
health system during their period of service in order for the
screening strategy cost to offset the treatment costs
avoided. And assuming a chronic HCV rate of 85% of the
observed rate of HCV seropositivity further increases the
net savings to $7.5 million with a break-even point of
36% (n 5 56) of the 158 cases of chronic HCV cases
being identified and treated during their period of service.
Last, assuming both a lower cost of treatment
($83,319) and a higher than observed rate of chronic
HCV (0.06%) increased the net savings to $4.0 million
with a break-even point of 50% (n 5 70) of the 139
cases of chronic HCV being identified and treated during their period of service.

Discussion
Screening for chronic HCV infection by EIA test followed by confirmation with NAT minimizes accessions of
HCV-infected applicants while reducing inappropriate

Fig. 1. Screening strategy. Bars show the total cost in millions of
U.S. dollars of each of the three policy options for HCV screening.
Each bar is color coded as identified above for the contributions of
testing, re-recruitment and treatment to the total cost.
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exclusion of fully qualified applicants. The use of confirmatory testing is important in stratifying risk and treatment decisions in individual patients, as discussed in
clinical guidelines.11,15 An EIA-only arm was important
to explore in this model as population screening aims
that refer individuals to other mechanisms for patient
evaluation and care may differ from usual clinical test
use. Systematic inclusion of NAT could require new
investments. Because the majority of all HCV infections
among US military personnel were present at accession,
an applicant screening program is likely to be the most
effective way to decrease the burden of HCV infection
among US military personnel, will decrease the threat
deployed service members with chronic HCV infection
pose to the emergency battlefield non-FDA blood supply,
and will likely result in opportunities for earlier diagnosis
and linkage to care for those identified with chronic
HCV infection. Accession screening is predicted to markedly reduce the burden of HCV infection in the deployable force, but given the low level of service-related
incidence of HCV infection, it will not entirely eliminate
HCV infection. Accession screening is predicted by this
model to result in a small system net cost savings due to
treatment costs avoided while also decreasing armed services prevalence of HCV.
The sample studied was representative of both the
accession population and the deployed force. All members of the deployed force were, by definition, accessions
who at one time were successful applicants for military
service. The accession population and the deployed
force do not necessarily reflect the entire applicant population, which includes both applicants who successfully
acceded and all those who did not. It is possible that the
applicant population that does not accede could differ
significantly from those applicants who do accede and
that the prevalence of HCV infection in these two
groups could differ. But these differences would have
only minimal impact on this model and would not significantly alter the findings.
HCV screening among more than 200,000 sailors
and Marines tested on accession as part of a pilot program at initial training depots in the period 2011-2013
yielded similar HCV prevalence rates as this study
(0.6/1000 and 0.4/1,000 person tested for HCV
antibody-positive and chronic HCV infection, respectively; C.G. Beckett, unpublished data). This study
had rates similar to those of Hyams et al.5 for younger
service members but a three-fold higher prevalence
among older service members (born before 1966).
And, overall, these results are consistent with evidence
driving current Centers for Disease Control recommendations on hepatitis C screening in the general

HEPATOLOGY, February 2016

population and those of the US Preventive Medicine
Task Force.6,16
All service-related HCV incidence occurred among
the younger birth cohort. All occurred among US-born
males in non-health care worker occupations, and most
occurred among white males in the Army. Behavioral
and personal exposure histories were not obtained as
part of this investigation, and given the small numbers
of infections, risk factors for incident infection cannot
be identified. Further study and a larger sample are
required to make any additional determination and recommendations regarding the potential utility and costs
associated with periodic screening of the force following
accession screening.
Emergent whole blood transfusion has been an important feature of combat casualty resuscitative care in the
conflicts in Iraq and Afghanistan. The US military uses
freshly collected blood products for life-threatening injuries when available stored blood components in theater
have been exhausted or when these components are
unsuccessful for resuscitation. Countermeasures in place
to reduce the risk of transfusion-transmitted infections
associated with use of these freshly collected products
include periodic and combat theater entrance screening
for human immunodeficiency virus (HIV), universal
HBV vaccination, use of prescreened blood donor pools,
a donor screening questionnaire, and point of collection
rapid diagnostic tests. DoD policy has included universal
HBV vaccination during initial entry training since 2001,
and all personnel who entered military service prior to
2001 who have not been vaccinated are required to initiate vaccination prior to entry into the combat theater of
operations. Volunteers at deployed facilities with blood
donation capacity are initially screened for HIV, HBV,
HCV, human T lymphotropic viruses I and II, West Nile
virus, and syphilis and rescreened each time they donate
and every 90 days after admission. And at the time of
donation, donated units are tested for HIV, HBV, and
HCV with rapid diagnostic tests. There are situations,
such as mass casualty or combat casualty care scenarios in
smaller military treatment facilities, where prepositioned
FDA-compliant blood component supplies are exhausted
and only limited screening of emergency blood donors is
possible. To date, one transfusion-transmitted HCV
infection has been documented, and this occurred in an
austere setting where no countermeasures were in place.2
Because most HCV infections among service members
who deploy were present at accession, an accession screening program will markedly reduce the number of
deployed service members with HCV infection who may
enter the battlefield blood. However, given the small
service-related incidence of chronic HCV infection,
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accession screening will markedly reduce but not entirely
eliminate this potential threat.
Test performance can have a marked impact on
observed prevalence and cost model outcomes. The sensitivity and specificity of the EIA test and NAT
employed in this cost model were based on the product
labels. HCV antigen tests have become increasingly
available. Their test sensitivity against NAT as a gold
standard may range from 50% to 90%.17 As these and
other assays become available, different screening strategies may be possible and subsequent cost models will
need to be developed to reevaluate the status quo.
The cost model presented was developed from the perspective of the DoD, and the return on investment was
based on a comparison between the costs associated with
initiating a screening program of applicants and the
potential treatment costs avoided by identifying applicants with HCV infection and barring them from entry
into military service. It is not possible to know prospectively how many HCV-infected applicants identified
through an accession screening program would have been
identified as infected and would have required treatment
during the course of their military service if there was no
accession or periodic force screening program. It is also
unknown how those active duty service members who are
identified, more than 200/year on average, every year
with chronic HCV infection came to be identified; and
no data are available regarding whether or not those
trends and rates of case identification would persist in the
future. This model was based on the assumption that case
finding would occur at similar rates and that the case
identification among active duty personnel in recent years
was stable. If trends resulting in case identification significantly changed prospectively, this model would have to
be adjusted accordingly.
The HCV treatment landscape is rapidly evolving.
Difficult treatment decisions, such as when to initiate
therapy, are strongly influenced by the high cost of treatment. Newer antiviral agents with activity against HCV
already have been incorporated into clinical practice
guidelines.11 Current treatment guidelines discourage
the use of older line treatments because they are inferior
to recommended treatment regimens and because most
of the interferon-containing regimens are associated
with higher rates of serious adverse events and have
many features that compromise compliance and completion of therapy including longer treatment duration,
numerous drug-drug interactions, and more frequent
dosing.11 The $100,000 cost of treating an HCVinfected accession used in this model was based upon
treatment using the new highly effective HCV treatment
including sofosbuvir. Newer drugs are very costly. As the
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range of therapeutic options grows (such as with the
licensure of the all-oral regimen of ledipasvir and sofosbuvir), more experience is gained in the operationalized
clinical performance of newer therapies, and market
pressures evolve pricing, the relative importance of
excluding versus accepting and treating HCV-infected
candidates may change. The value of screening may
change from excluding candidates to the importance of
early identification for treatment initiation and lower
long-term system costs. For now, the cost of treatment
remains high.
Clinical and exposure data for cases identified in this
investigation, including risk factors for infection, duration of infection, and fibrosis score, were not obtained.
This model assumed that all cases of chronic HCV
infection identified would be treated. Offering therapy
is the standard of care. Delays in therapy for some
patients because of resource or other issues could impact
the cost model and conclusions from the perspectives of
both the DoD and other government agencies such as
the Veterans Administration which could experience
cost shifting.
This cost model was developed from the perspective
of the DoD. However, a screening program that resulted
in earlier identification of individuals with chronic
HCV infection could lead to earlier diagnosis, linkage
to care, and treatment which could both benefit individual health and improve public health. From the perspective of the infected individual and society’s willingness
to pay, one analysis of switching to all-oral therapy identified a cost of approximately $80,000 per qualityadjusted life year.18 In more recent analyses considering
sofosbuvir, costs ranged widely, from less than $10,000
to nearly $300,000 per quality-adjusted life year
depending on patient and virus factors.13,19,20 Incorporation of other novel agents drove costs up to six times
higher.21 Many of these analyses have incremental costeffectiveness ratios per quality-adjusted life year that far
exceed the generally accepted threshold of US society’s
willingness to pay of $100,000.00.20 It is unclear at this
time, however, when and how these individual benefits
might be realized in the setting of a DoD applicant
screening program. Many of the applicants identified
with chronic HCV infection and barred from entry into
the armed forces may have early HCV infection given
their relative youth and may lack the resources necessary
or may not qualify for programs that provide care and
treatment.
The impact on diversity of the force of an HCV applicant screening program is likely minimal. The impact of
HCV-infected applicant exclusion on diversity is difficult
to quantify, though the total number of applicant
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exclusions across the more than 200,000 accessions
would be very low, so presumably the impact would be
minimal. A new assessment of national HCV incidence
highlighted white nonurban young adults as a growing
pool of infected persons.22 This same report identified a
150% increase in HCV case reporting between 2010
and 2013, highlighting the potential importance of
screening initiatives. Like any large-scale screening initiative, prospective operational public health research
would be necessary in order to enable comprehensive
monitoring, assessment, and intervention of program
performance as well as identifying health improvement
opportunities.
While contemporary hepatitis C seroprevalence rates
are lower than among those born before 1966, in the
setting of the deploying military force, costs associated
with infection are nontrivial. Screening strategies here
provided small absolute cost benefits when modeled.
There also are implied value benefits regarding safety of
the walking blood bank in the deployed setting through
less chance of HCV infection among personnel in the
field.
This study employed reposed sera from the DoD
Serum Repository. This repository has a long history of
successful use with serologic testing, but performance
related to NAT is less clear. This may have resulted in
underestimation of chronic HCV infection when NAT
was employed for confirmation. However, this potential
limitation is mitigated by the fact that a higher than
observed prevalence of chronic HCV infection prospectively among the applicant population would make
applicant screening even more favorable. Other potential limitations include the fact that differences exist
among the total force between those who deploy and
those who do not deploy, that performance and costs of
diagnostic assays and therapies are evolving, and that
attention to HCV genotype was not given. Missing data
were also problematic, particularly with regard to birth
location. And direct comparison with similar studies of
cost in civilian settings is limited by the fact that they do
not incorporate the additional occupational costs and
consequences incurred by the military with any health
condition. Cost modeling here for HCV treatment in
active duty military personnel sought to minimize the
presence of personnel with permissive chronic viremia,
in the setting where most HCV cases identified in this
study had been infected for at least several years. It
assumed immediate treatment of disease in a setting
where clinical care is well resourced. This cost model
obtains savings through exclusion of HCV-infected
applicants. In the future, as cost of treatment approaches
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rerecruitment cost (Table 1), this strategy could be
reassessed.
In conclusion, despite decreased hepatitis C seroprevalence in deployed service members born after 1965,
screening by EIA test followed by confirmation with
NAT will minimize accession of HCV-infected applicants while reducing inappropriate exclusion of applicants. An applicant screening program will also
markedly reduce the burden of chronic HCV infection
in the overall force, will result in a small system costs
savings of approximately $3 million per year due to
decreases in treatment costs to the military health care
system, will decrease the threat of transfusiontransmitted HCV infection in the emergent battlefield
non-FDA blood supply posed by HCV-infected personnel, and may provide an opportunity for individuals
with chronic HCV infection to obtain earlier diagnosis
and linkage to care and treatment. Initiation of an applicant screening program will require ongoing evaluation
that considers changes in the treatment cost and practice
landscape, screening options, and the epidemiology of
HCV in the applicant/accession and overall force populations. Future study to more fully characterize the epidemiology of incident, service-related chronic HCV
infection is also recommended; and those findings will
inform policy regarding population-based screening and
contribute to countermeasures intended to ensure the
safety of the battlefield blood supply.
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